[3',5'-cAMP phosphodiesterase inhibitors in the combined treatment of patients with rheumatoid arthritis].
A study was made of clinical effectiveness and mechanism of action of the inhibitor of the specific 3',5'-cAMP phosphodiesterase papaverine in a therapeutic complex of measures designed to treat RA patients involving an immunodepressive preparation free from any cytopenic effect prospidin as a basic mediator. It has been shown that the papaverine antiarthritic action is associated with its positive effects on the unspecific component of the immune-complex inflammation, viz. processes of lipid peroxidation, activity of the antioxidant system of defence as well as on the vascular tone and microcirculation. All this improves tissue metabolism, and in this way enhances efficiency of RA basic therapy.
Bakaliuk
O I
OI
Shved
M I
MI
Hrebenyk
M V
MV
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D005954:Glucosephosphate Dehydrogenase / Q000097:blood / Q000187:drug effects; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007113:Immunity, Innate / Q000187:drug effects; D015227:Lipid Peroxidation / Q000187:drug effects; D010208:Papaverine / Q000627:therapeutic use*; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D011447:Prospidium / Q000627:therapeutic use
D018501:Antirheumatic Agents; D010726:Phosphodiesterase Inhibitors; D011447:Prospidium; D010208:Papaverine; D005954:Glucosephosphate Dehydrogenase; D015105:3',5'-Cyclic-AMP Phosphodiesterases
Inhibitory 3'--5'-tsAMF-fosfodiiesterazy v kompleksnomu likuvanni khvorykh na revmatoïdnyĭ artryt.